GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Second Quarter Ending June 30th, 2020 and Host Conference Call on August 6th, 2020
GW Pharmaceuticals plc (Nasdaq: GWPH) will release its financial results and operational updates for Q2 2020 on August 6, 2020. The announcement will be accompanied by a conference call at 4:30 p.m. EDT. GW is recognized for its proprietary cannabinoid product platform, particularly EPIDIOLEX, which treats seizures in patients with Lennox-Gastaut and Dravet syndromes. The company aims to expand EPIDIOLEX's indications and is advancing multiple cannabinoid candidates in late-stage clinical trials.
- Positive Phase 3 data reported for EPIDIOLEX's expansion to Tuberous Sclerosis Complex.
- Multiple late-stage clinical programs for nabiximols seeking FDA approval.
- None.
LONDON and CARLSBAD, Calif., July 23, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on August 6th, 2020 its financial results and operational progress for the second quarter ending June 30th, 2020. GW will also host a conference call the same day at 4:30 p.m. EDT. Conference call information will be provided in the financial results press release and on the Company website (www.gwpharm.com) in the investor section. A replay of the call will also be available through the Company's website shortly after the call.
About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.
Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older. The Company has submitted applications in both the U.S. and Europe to expand the indication for Epidiolex to include seizures associated with Tuberous Sclerosis Complex (TSC), for which it has reported positive Phase 3 data, and is carrying out a Phase 3 trial in Rett syndrome. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury, as well as for the treatment of PTSD. The Company has additional cannabinoid product candidates in Phase 2 trials for autism and schizophrenia. For further information, please visit www.gwpharm.com.
Enquiries:
| 29%; width: | 71%; width: |
| Stephen Schultz, VP Investor Relations (U.S.) | 917 280 2424 / 401 500 6570 |
FAQ
When will GW Pharmaceuticals announce its Q2 2020 financial results?
What is the purpose of the conference call on August 6, 2020?
What product does GW Pharmaceuticals focus on?
What new conditions is GW Pharmaceuticals expanding EPIDIOLEX's indications to?
